<DOC>
	<DOCNO>NCT00647829</DOCNO>
	<brief_summary>The study perform evaluate analgesic efficacy , safety , tolerability valdecoxib 20 mg twice daily ( BID ) , valdecoxib 40 mg daily ( QD ) , placebo patient moderately severely painful symptomatic sore throat 24-hour period . In addition , study validate new scale criterion measure pain sore throat evaluate effect selective serotonin reuptake inhibitor past sore throat pain pain score efficacy analgesic . The study also examine type medication commonly use sore throat whether information relevance analgesic efficacy .</brief_summary>
	<brief_title>A Comparison Of Valdecoxib 20 Mg Twice Daily 40 Mg Daily Placebo In The Treatment Of Sore Throat</brief_title>
	<detailed_description />
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Valdecoxib</mesh_term>
	<criteria>Included patient moderate severe pain , measure Sore Throat Pain Intensity Scale ( STPIS ) swallow â‰¥66 mm 100mm visual analogue scale ( VAS ) minimum 4 point 10point TonsilloPharyngitis Score ( TPS ) cough experience evidence mouthbreathing . Patients use throat lozenge , throat spray , cough drop mentholcontaining product within 2 hour , shortacting analgesics/antipyretics ( eg , ibuprofen ) form cold medication within 8 hour , antibiotic acute disease within 24 hour first dose study medication , presume diagnosis infectious mononucleosis , know allergy hypersensitivity NSAIDs , COX2 specific inhibitor , sulfonamide , acetaminophen exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>pharyngitis , sore throat</keyword>
</DOC>